Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.

Cancer research·2026
Same author

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same author

Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358].

Critical reviews in oncology/hematology·2026
Same author

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

Frontiers in oncology·2026
Same author

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

Journal of experimental & clinical cancer research : CR·2026
Same author

Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma.

Scientific reports·2026

Related Experiment Video

Updated: Jul 18, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Targeted therapies in Ewing's sarcoma.

Katia Scotlandi1

  • 1Growth Factors and Receptors, Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy. katia.scotlandi@ior.it

Advances in Experimental Medicine and Biology
|December 14, 2006
PubMed
Summary

New targeted therapies against insulin-like growth factor receptor I (IGF-IR) and CD99 show promise for treating aggressive Ewing's sarcoma. These innovative treatments, combined with chemotherapy, offer new hope for improving patient survival rates.

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Related Experiment Videos

Last Updated: Jul 18, 2026

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ewing's sarcoma is an aggressive bone cancer with poor survival rates despite current multimodal treatments.
  • There is a critical need for novel therapeutic strategies to combat this challenging pediatric neoplasm.
  • Targeting specific molecular pathways, such as insulin-like growth factor receptor I (IGF-IR) and CD99, presents promising avenues for intervention.

Purpose of the Study:

  • To evaluate the efficacy of tailored therapies targeting IGF-IR and CD99 in Ewing's sarcoma.
  • To assess the potential of combining these targeted therapies with conventional chemotherapy.
  • To investigate the therapeutic effects on primary tumors and distant metastases, as well as potential toxicities.

Main Methods:

  • In vivo studies using athymic mice bearing Ewing's sarcoma.
  • Administration of targeted therapies against IGF-IR and CD99, both as monotherapy and in combination with chemotherapy.
  • Evaluation of tumor growth, metastasis, apoptosis, and toxicological profiles.

Main Results:

  • Targeted therapies against IGF-IR and CD99 demonstrated significant anti-cancer effects on Ewing's sarcoma.
  • Combination therapies showed potential for enhanced efficacy and optimized treatment schedules.
  • Initial toxicological assessments were conducted to inform future clinical applications.

Conclusions:

  • Targeted inhibition of IGF-IR and CD99 represents a viable therapeutic strategy for Ewing's sarcoma.
  • Combination approaches with conventional chemotherapy warrant further investigation for improved clinical outcomes.
  • These findings provide a rationale for developing clinical trials of novel targeted therapies for Ewing's sarcoma.